What Вазавитал Treats: Main Uses and Benefits

---

The therapeutic application of Вазавитал, driven by its role as a microcirculation improver, addresses symptom patterns in three distinct, yet related, circulatory and neurological domains. It is generally used to provide supportive symptomatic relief in conditions characterized by periods of heightened symptoms. Within this context, the standardized extract is relevant for use in age-related cognitive issues and minor circulatory problems.

The medication is considered relevant for easing symptoms related to cerebral insufficiency, chronic peripheral circulatory disorders (including intermittent claudication), and specific forms of dizziness, vertigo, and tinnitus.

Supporting Cognitive Function and Circulation

This medication is commonly used to help with symptoms associated with age-related decline in cerebral function and mild cognitive impairment. It assists in managing symptom clusters such as difficulty concentrating, minor memory lapses, and reduced attentiveness. The benefit may assist with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods.

It is also applied in conditions presenting with systemic or localized discomfort related to chronic peripheral circulatory disorders. The core benefit provides supportive relief that contributes to improved comfort during symptomatic periods and may assist with managing symptoms related to walking, as well as disturbances like dizziness and tinnitus.

“The supportive relief provided contributes to general well-being during symptomatic phases and helps patients cope more steadily with their day-to-day challenges.”

Quick Fact: Relief for Chronic Circulatory Symptoms

The medication is applied in managing chronic symptoms of peripheral circulation that may interfere with daily comfort, such as coldness or heaviness in the limbs.

Regulatory References

1. European Medicines Agency HMPC on Ginkgo leaf

Official Eligibility and Non-Eligibility Rules

Eligibility to use Вазавитал is determined by strict criteria set out in official regulatory documents for Ginkgo biloba extract. Use is primarily established for Adults and the Older Adult (Geriatric) population.

Absolute Contraindications

Use is contraindicated and must be avoided in the following populations:

• Patients with known hypersensitivity to the active substance or any excipients.
• Individuals with pre-existing bleeding disorders or hemorrhagic diathesis.
• Pregnant women are prohibited from using the medicine due to the antiplatelet properties and lack of sufficient safety data.

Restricted and Non-Recommended Populations

Population Group	Regulatory Status
Children & Adolescents (Under 18)	Not Recommended due to insufficient data on efficacy and safety.
Lactation (Breastfeeding)	Not Recommended in the absence of data on excretion into human milk.
Pre-operative Patients	Must discontinue the medicine at least 2 weeks prior to scheduled surgery.
Epilepsy Patients	Use requires caution, as further seizures cannot be ruled out.

Eligibility is defined by regulatory bodies through these classifications, ensuring use is restricted to populations where clinical experience or data is adequate and where absolute contraindications are absent.

Interactions with other medicines and products

This section details the officially documented interaction profile for the Ginkgo biloba extract in Вазавитал, based strictly on government regulatory documents.

Pharmacodynamic and Bleeding Risk

The most prominent officially documented interaction relates to blood clotting. The product's potential to affect platelet aggregation requires caution when co-administered with Anticoagulants (such as Warfarin or Phenprocoumon) and Antiplatelet drugs (including NSAIDs and Clopidogrel), as the combined effect may increase the susceptibility to bleeding.

Pharmacokinetic Interactions

Interactions that alter the plasma concentration of other medicines are documented due to the product's effect on certain metabolic pathways and transporters:

• Efavirenz: Concomitant use is not recommended due to official documentation of CYP3A4 induction, which may lead to a decrease in Efavirenz plasma concentrations.
• Dabigatran etexilate: The product may inhibit P-glycoprotein (P-gp), potentially resulting in increased exposure of Dabigatran.
• Nifedipine: An increase in the maximum concentration ( C max) of Nifedipine has been observed in some individuals.

Timing and Population-Specific Restrictions

• Pre-Surgical Requirement: The product must be discontinued as a precaution 3 to 4 days prior to any surgical procedure to reduce the risk of excessive bleeding, as defined in regulatory labeling.
• Epilepsy Patients: Onset of further seizures in patients with epilepsy cannot be excluded, a population-specific note cited in official documents.
• Pregnancy: Use during pregnancy is contraindicated due to the risk of increased bleeding tendency.

The mechanism of action for Вазавитал centers exclusively on modulating specific vascular and cellular pathways, influencing microcirculatory function and cellular resilience. This dual approach is driven by the standardized concentration of its two core active constituent groups: flavonoid glycosides and terpenoid lactones.

Modulating Microvascular Dynamics and Blood Fluidity

This domain defines the mechanism of the drug's effect on the physical properties of blood and vessel diameter. The terpenoid lactones, particularly Ginkgolide B, act as antagonists of the Platelet-Activating Factor Receptor (PAF-R). By blocking this receptor, the extract causes an inhibition of excessive platelet aggregation and facilitates blood flow. In parallel, certain components stimulate the release of Nitric Oxide (NO) from the endothelium, leading to the relaxation of vascular smooth muscle. The resulting physiological effect is an increase in microcirculatory perfusion and a change in blood characteristics, such as viscosity, in both central (cerebral) and peripheral vessels.

Influencing Neurocellular Response to Oxidative Activity

This domain focuses on the extract’s ability to influence tissues, especially in the central nervous system, under conditions of oxidative activity. The flavonoid glycosides are free radical scavengers, neutralizing Reactive Oxygen Species (ROS) that contribute to oxidative processes. This action is critical for stabilizing key cellular components, including mitochondrial membranes, against the effects of metabolic and ischemic processes. The resulting physiological effect is a modulation of cellular response to conditions of reduced oxygen supply and oxidative stress, influencing structural and functional integrity.

The usage protocol for Вазавитал is based on the standardized parameters for its active component, Ginkgo biloba leaf extract. The medicine is intended for oral administration in the form of a capsule or tablet.

The standard adult daily dose for the extract typically ranges from 120 mg to 240 mg. To maintain a consistent administration schedule, this total dose is commonly divided into two or three separate administrations per day. The unit dose should be swallowed whole, generally with water, and is often advised to be taken with or immediately following a meal.

Regarding the duration of use, the official guidance defines a necessary course period before the continuation of the regimen is assessed. For symptoms related to age-associated cognitive function, a duration of at least eight continuous weeks is recommended before determining the benefit of the administration. The use of the medicine is not recommended for individuals under the age of 18 due to a lack of sufficient data for this population. If a scheduled dose is missed, it is advised against taking a double dose to compensate; instead, the regular schedule should be continued with the next planned dose.

The official instructions define the required route (oral) and frequency (divided daily dose) along with the specific minimum time frame for administration (8 weeks), establishing a structured approach to the medicine's use.

Research Evidence / Overview of Studies for Вазавитал

---

Evidence for Use in Age-Related Cognitive Function

Research involving Randomized Controlled Trials (RCTs) and meta-analyses has examined whether the standardized Ginkgo biloba extract used in this medicine may be associated with changes in symptoms of mild cognitive impairment and age-related decline. Studies monitored cognitive test scores and measures of daily function. In populations with existing mild cognitive impairment, some trials reported that changes in symptomatic scores related to memory and concentration were measured during the study period. However, findings regarding quality of life and psychiatric symptoms were often mixed and inconsistent across various systematic reviews.

Large, long-term trials (lasting up to five or six years) in healthy, cognitively normal older adults did not suggest a clear difference in the rate of developing dementia when compared to a placebo. This means long-term effects for prevention are not fully established, and the research focuses on long-term cognitive outcomes in general.

---

Evidence for Use in Chronic Peripheral Circulation

The extract has been examined in adults with intermittent claudication (pain when walking due to restricted circulation). Studies mainly measured pain-free walking distance and maximum walking distance. Systematic reviews generally described that the magnitude of reported change in walking distance was small, and the clinical relevance of this pattern is a matter of ongoing discussion in the literature. For minor circulatory symptoms, regulators have noted the extract's long history of use, and the extract is applied in research contexts involving fluctuating symptoms. Comparative evidence against established standard therapies for peripheral artery disease is limited.

---

Evidence for Use in Dizziness and Tinnitus

Research has explored whether the extract's use was associated with changes in subjective symptoms like dizziness, vertigo, and chronic tinnitus. Findings are often mixed and inconsistent. For chronic tinnitus (ringing in the ears), many high-quality systematic reviews indicate that the extract's measured outcomes were comparable to those observed with an inactive placebo, and research has not established a consistent pattern of sustained relief. The evidence for dizziness and vertigo is similarly inconsistent and limited across various studies. Follow-up durations in most symptomatic studies were short (around six months), meaning long-term effects are not fully established or well characterized.

Common questions about Вазавитал (FAQ)

Q: What are the most common or minor side effects people report with Вазавитал?

According to official product information, common side effects reported by users include headache, certain gastrointestinal disorders (such as stomach upset), and mild allergic skin reactions. The full safety information section details less frequent and more serious potential effects.

Q: Is it normal to feel a slight headache when starting Вазавитал?

Official regulatory safety documents list headache as a common side effect associated with this medicine. If symptoms are persistent or severe, individuals should consult their healthcare provider.

Q: Can taking Вазавитал affect my sleep?

Official regulatory documents indicate that potential side effects can include central nervous system effects such as drowsiness and sleep problems (specifically insomnia). If these effects occur, review the full product safety information.

Q: What is the recommended time of day to take Вазавитал?

Regulatory instructions advise that the total daily dose is typically divided and should be taken with or immediately following a meal. A specific time of day, such as morning or evening, is not usually specified in the core regulatory guidance.

Q: Are there any food restrictions while taking Вазавитал?

Official labeling does not document specific food restrictions that must be avoided while taking this medicine. It is commonly advised to be taken with or immediately following a meal for optimal use.

Q: Does Вазавитал have any potential interactions with caffeine or alcohol?

Official information generally advises that concomitant use with alcohol is not advisable, as it may enhance side effects such as dizziness. Interactions with caffeine are not consistently documented in core regulatory safety texts.

Q: Does Вазавитал interact with common pain relievers like ibuprofen?

Official regulatory documents caution that taking this product with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which includes ibuprofen, may increase the susceptibility to bleeding. This combination requires caution due to the product’s antiplatelet effects.

Q: Is it safe to drive or operate machinery while taking Вазавитал?

Due to the potential for side effects such as dizziness and drowsiness, activities requiring concentration, such as driving or operating machinery, should be avoided until the individual is aware of how the medicine affects them.

Q: Can Вазавитал be used by people with diabetes?

Regulatory documents advise caution for individuals with diabetes. Individuals with diabetes should seek advice from a healthcare provider, as the product has the potential to interfere with diabetes medication.

Q: How does Вазавитал affect blood pressure?

Regulatory data generally suggests no clear or significant effect on blood pressure in most individuals. The mechanism is related to improving blood flow. Patients with pre-existing hypertension should discuss their condition with a healthcare provider before use.

Q: Does Вазавитал affect liver enzymes or kidney function?

Official safety warnings advise caution for individuals with pre-existing liver or kidney impairment and recommend they seek professional medical advice. While the exact effect on enzymes is complex, these conditions may affect how the body processes the medicine.

Q: Has Вазавитал been approved by major regulatory bodies in different countries?

The active ingredient is documented in the European Medicines Agency (EMA) Monograph as an established herbal medicinal product. This confirms its official regulatory status for therapeutic use in EU Member States.

Q: Why do some people take Вазавитал for issues with dizziness?

Regulatory documents note that the product is traditionally used for symptoms like dizziness and vertigo. This use is associated with its application in addressing minor circulatory disorders.

Q: Is Вазавитал suitable for people who have sensitive stomachs?

Official safety documents list gastrointestinal disorders such as stomach upset, nausea, diarrhea, and constipation as known side effects. Those who have sensitive stomachs may wish to discuss this risk with a healthcare provider.

Q: Where is Вазавитал typically stored (e.g., room temperature)?

Storage instructions state the product must be kept in the original package to protect it from moisture and light. It should not be stored at temperatures above 25 C (77 F).

How to Store and Dispose of Вазавитал?

Storage and disposal must strictly adhere to regulatory labeling to maintain product stability and ensure environmental safety.

Storage Requirement	Rule as Stated in Official Labeling
Temperature	Do not store at temperatures above 25 C (77 F).
Protection	Store in the original package to protect the capsules from moisture and light.
Child Safety	Keep out of the sight and reach of children.
Stability	Do not use after the expiry date printed on the carton.

For disposal, unused or expired Вазавитал must not be thrown into household waste or disposed of via wastewater. The product must be taken to a pharmacist or a designated local collection point to ensure pharmaceutical waste is handled correctly and to protect the environment.